ABCL-185 Mosunetuzumab wWth Polatuzumab Vedotin: Subgroup Analyses in Patients (pts) With Primary Refractory or Early Relapsed Large B-Cell Lymphoma (LBCL)

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Clinical Lymphoma Myeloma & Leukemia

Topics

Physics

Cancer Oncology

Medicine

Internal Medicine

Pathology And Forensic Medicine

Show all topics

DOI

10.1016/s2152-2650(24)01494-0